Get the content you want anytime you want.
REGISTER NOW | SIGN IN
IAS 2017 Conference

Select coverage from IAS 2017 Conference is included below:

Novel PHIA Project Collecting HIV Biomarkers in Children
Jessica Justman, MD, shares how the PHIA project is collecting HIV biomarkers in children.
Long-Acting Injectable: An Exciting New Option for HIV Prevention
Alex Rinehart, PhD, explains how the development of a long-acting injectable offers a new preventive option for HIV.
Challenges Faced When Creating a Vaccine for HIV
Hanneke Schuitemaker, PhD, explains the challenges faced when creating a vaccine for HIV.
What Were the Results of the Phase 3 EMERALD Trial?
Magda Opsomer, MD, shares the results of the Phase 3 EMERALD trial for darunavir.
How Can Decision Makers Use the Population-based HIV Impact Assessment Project Data?
Jessica Justman, MD, explains how decision makers can use the Population-based HIV Impact Assessment Project data.
Does Cabotegravir Interact with Any Other Medications?
Alex Rinehart, PhD, explains if cabotegravir interacts with any other medications.
Latest Results of the Population-Based HIV Impact Assessment Project
Jessica Justman, MD, reveals the latest results of the Population-based HIV Impact Assessment Project (2017).
Who is the Target Population for Cabotegravir?
Alex Rinehart, PhD, identifies the target population for cabotegravir.
FEATURED
Big advances in treatment can